RiverPark Advisors LLC Has $425,000 Position in Natera, Inc. (NASDAQ:NTRA)

RiverPark Advisors LLC grew its stake in Natera, Inc. (NASDAQ:NTRA) by 3.5% during the third quarter, HoldingsChannel reports. The firm owned 3,347 shares of the medical research company’s stock after buying an additional 112 shares during the quarter. RiverPark Advisors LLC’s holdings in Natera were worth $425,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. SG Americas Securities LLC raised its holdings in Natera by 1,073.1% in the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock valued at $7,118,000 after buying an additional 60,127 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Natera by 15.1% in the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after buying an additional 9,781 shares during the last quarter. Natixis bought a new position in Natera in the 1st quarter valued at approximately $758,000. Chartwell Investment Partners LLC raised its holdings in Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft bought a new position in Natera during the 2nd quarter worth approximately $478,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Stock Down 3.3 %

Shares of NASDAQ:NTRA opened at $146.06 on Friday. The company’s 50-day moving average is $127.38 and its 200 day moving average is $115.61. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.01. Natera, Inc. has a fifty-two week low of $52.01 and a fifty-two week high of $167.79.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm’s quarterly revenue was up 63.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.95) EPS. Equities analysts forecast that Natera, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on NTRA shares. TD Cowen raised their price target on shares of Natera from $155.00 to $175.00 and gave the stock a “buy” rating in a report on Wednesday. Sanford C. Bernstein lifted their price objective on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. UBS Group lowered their price objective on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research note on Friday, August 9th. The Goldman Sachs Group lifted their price objective on shares of Natera from $125.00 to $140.00 and gave the company a “buy” rating in a research note on Wednesday, October 16th. Finally, StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $137.65.

Insider Buying and Selling at Natera

In other news, insider Solomon Moshkevich sold 1,196 shares of the company’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $118.21, for a total transaction of $141,379.16. Following the sale, the insider now directly owns 110,695 shares in the company, valued at $13,085,255.95. This represents a 1.07 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 5,024 shares of the company’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the transaction, the chief executive officer now owns 195,686 shares in the company, valued at approximately $25,141,737.28. This trade represents a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 36,821 shares of company stock valued at $4,776,878 over the last three months. 7.60% of the stock is currently owned by insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.